Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer
Journal of Korean Medical Science
;
: e178-2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-715018
ABSTRACT
BACKGROUND:
Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).METHODS:
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.RESULTS:
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0–150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL, P < 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (P = 0.014).CONCLUSION:
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Plasma sanguin
/
Trétinoïne
/
Test ELISA
/
Marqueurs biologiques
/
Fumer
/
Protéines de transport
/
Marqueurs génétiques
/
Taux de survie
/
Mortalité
/
Carcinome pulmonaire non à petites cellules
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Journal of Korean Medical Science
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS